ACTICOR BIOTECH (FR0014005OJ5 – ALACT), a clinical stage biopharmaceutical company developing glenzocimab, an innovative drug for the treatment of cardiovascular emergencies, today provides an update on the current receivership proceedings. To enable the Company to continue its search for new investors or partners to support its new development plan in STEMI (ST-Elevation Myocardial Infarction), the court-appointed administrator had granted mid-October 2024 an extension until Tuesday November 5, 2024, to the call for bids published on...